PRQR — ProQR Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $182.05m
- $68.00m
- €16.35m
ProQR Therapeutics NV reports results for the quarter ended March 31 - Earnings Summary
ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview
Brief: Proqr Therapeutics NV Files For Shelf Of Up To Up To 3.5 Million Ordinary Shares By Selling Stockholder - SEC Filing
ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
U.S. STOCKS ON THE MOVE-Coca-Cola, Spirit Airlines, Boeing
ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in
Brief: PROQR Therapeutics NV Prices Public Offering Of 18 Million Shares At $3.50 Each
Brief: Proqr Announces Proposed Underwritten Public Offering Of Ordinary Shares
Brief: ProQr Therapeutics NV Files For Mixed Shelf Offering Of Up To $300 Million
ProQR Therapeutics NV reports results for the quarter ended in June - Earnings Summary
ProQR Therapeutics NV expected to post a loss of 12 cents a share - Earnings Preview
ProQR Therapeutics NV reports results for the quarter ended in March - Earnings Summary
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
Brief: ProQR Therapeutics NV Intends To Change Board Structure From Two-Tier Structure To One-Tier Board
Brief: Proqr Therapeutics Completes Transaction For Théa To Acquire Sepofarsen And Ultevursen Ophthalmic Assets
Brief: ProQR Therapeutics Q3 basic EPS EUR -0.07
ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview